⁃ Must freely sign informed consent;

⁃ Aged 18 to 80 years old;

⁃ Histologically or cytologically confirmed diagnosis of esophagus cancer;

⁃ ECOG score is 0 or 1;

⁃ completed Neoadjuvant combined with PD-1 therapy ;Completed surgical resection ;At the same time, standard postoperative treatment was performed 8 \

• 12 weeks of therapy;

⁃ Must provide all exons of tumor tissue sequencing data, transcriptome sequencing data and the peripheral blood of all exons sequencing data;

⁃ Completion of imaging records 1 week before personalized immunotherapy, including but not limited to full-body PET-CT and brain MRI,

⁃ Haematological index： White blood cells ≥ 3500 / MCL; Lymphocytes \> 800/ MCL; neutrophils \> 1500/ MCL; Platelets \> 100000 / MCL; Hemoglobin \>10.0g/dL; Total serum bilirubin \<1.5× upper limit of normal value (ULN); AST/ALT\<2.0 times the upper limit of normal; Serum creatinine \<1.5 times the upper limit of normal；

⁃ Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial;

‣ Male patients are willing to take appropriate methods of contraception;

‣ Good compliance, able to follow research protocols and follow-up procedures;